Consensus Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Real-time Estimate Cboe BZX Other stock markets 12:28:08 2024-04-19 pm EDT			5-day change	1st Jan Change
156.4 ^USD	-4.61%		-9.73%	+26.34%

Apr. 16	Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	MT
Mar. 12	Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Krystal Biotech, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a17f5188f425929e2cacaf8d4.GOymSCoSWYEwxDVGl0pxIx9YFQBxsqFkwH7SG-WnfL8.fYrnAGwhPulqvXMX8DsQRzJuXS0U2-tT8C6gcZ3KN9lhs5MREkg_2EO1Vg~8d0a307e43234d9ae70d59e0d27e1f31

Analyst Recommendations on Krystal Biotech, Inc.

Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	Apr. 16	MT
Cantor Fitzgerald Initiates Krystal Biotech With Overweight Rating, Price Target is $160	23-10-24	MT
Citigroup Initiates Krystal Biotech at Buy Rating With $160 Price Target	23-10-12	MT
Berenberg Initiates Coverage on Krystal Biotech at Buy, $154 Price Target	23-09-07	MT
Chardan Ups Price Target on Krystal Biotech to $153 From $148, Keeps Buy Rating	23-08-08	MT
BofA Securities Adjusts Krystal Biotech Price Target to $140 From $118, Maintains Buy Rating	23-05-25	MT
Stifel Increases Price Target on Krystal Biotech to $145 From $102, Maintains Buy Rating	23-05-24	MT
Goldman Sachs Adjusts Price Target on Krystal Biotech to $155 From $135, Keeps Buy Rating	23-05-22	MT
Guggenheim Adjusts Price Target on Krystal Biotech to $130 From $101, Maintains Buy Rating	23-05-22	MT
HC Wainwright Adjusts Price Target on Krystal Biotech to $139 From $119, Keeps Buy Rating	23-05-22	MT
Chardan Raises Price Target on Krystal Biotech to $148 From $133, Keeps Buy Rating	23-05-22	MT
BofA Securities Adjusts Price Target on Krystal Biotech to $118 From $105, Keeps Buy Rating	23-05-22	MT
Stifel Starts Krystal Biotech at Buy With $102 Price Target	23-04-18	MT
Goldman Sachs Upgrades Krystal Biotech to Buy From Neutral, Adjusts Price Target to $124 From $79	23-02-28	MT
Chardan Lifts Price Target on Krystal Biotech to $133 From $130, Reiterates Buy Rating	22-11-08	MT
HC Wainwright Adjusts Price Target on Krystal Biotech to $119 From $107, Maintains Buy Rating	22-11-07	MT
Goldman Sachs Downgrades Krystal Biotech to Neutral From Buy; Price Target is $74	22-08-25	MT
Chardan Research Adjusts Price Target on Krystal Biotech to $130 From $137, Citing Q2 Results, Spend Forecasts; Buy Rating Kept	22-08-09	MT
Goldman Sachs Adjusts Price Target for Krystal Biotech to $78 From $91, Keeps Buy Rating	22-05-24	MT
Guggenheim Adjusts Krystal Biotech's Price Target to $101 From $114, Reiterates Buy Rating	22-03-29	MT
Chardan Research Lowers Price Target for Krystal Biotech to $137 From $140, Maintains Buy Rating	22-03-11	MT
Goldman Sachs Adjusts Krystal Biotech Price Target to $93 From $125, Maintains Buy Rating	22-03-01	MT
HC Wainwright Adjusts Krystal Biotech's Price Target to $107 from $124, Maintains Buy Rating	22-02-28	MT
BofA Securities Starts Krystal Biotech at Buy With $110 Price Target	22-01-18	MT
Goldman Sachs Hikes Krystal Biotech's Price Target to $125 From $85, Maintains Buy Rating	21-11-29	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

164 USD

Average target price

188.5 USD

Spread / Average Target

+14.96%

High Price Target

208 USD

Spread / Highest target

+26.85%

Low Price Target

153 USD

Spread / Lowest Target

-6.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Krystal Biotech, Inc.

Stifel Nicolaus
Cantor Fitzgerald
Citigroup
Berenberg Bank
Chardan Research
BofA Securities
Goldman Sachs
Guggenheim
HC Wainwright
Evercore ISI
Cowen
Chardan
JonesTrading Institutional Services

Ratings for Krystal Biotech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar